ACT 001

Drug Profile

ACT 001

Alternative Names: ACT001

Latest Information Update: 14 Jun 2016

Price : $50

At a glance

  • Originator Accendatech
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 14 Jun 2016 Pharmacodynamics and adverse events data from a preclinical trial in Solid tumours released by Accendatech
  • 14 Jun 2016 Accendatech has patent protection for ACT 001 in USA, European Union, China, Russia, South Korea and Japan
  • 14 Jun 2016 Accendatech plans a phase I trial for Solid tumours in Australia (ACTRN12616000228482)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top